May 16, 2012 -- Novozymes Biopharma, the pharmaceutical subsidiary of Novozymes A/S, a Swedish maker of industrial enzymes, has begun selling hyaluronic acid that is made at its new Tianjin facility. Novozymes’ HA product is manufactured via a Bacillus-based process, while conventionally produced HA is derived from rooster combs or strains of Streptococcus bacteria. In comparison to its competitors’ HA, Novozymes says its HA is less prone to impurities or viral contamination. More details....
Stock Symbols: (NSDQ OMX: Copenhagen: NZYM B)
